Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 96
- Registration Number
- NCT04661137
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 586
- Registration Number
- NCT04458831
- Locations
- 🇺🇸
University of Arkansas Medical Sciences Site Number : 8400021, Little Rock, Arkansas, United States
🇺🇸St. Joseph Heritage Healthcare Site Number : 8400008, Fullerton, California, United States
🇺🇸University of California San Francisco (PARENT) Site Number : 8400009, San Francisco, California, United States
KRDI in Transplant-Eligible MM
- Conditions
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04430894
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT04287855
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 306
- Registration Number
- NCT04268498
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT04191616
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille Cedex, France
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇮🇹Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, Italy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Andrew Yee, MD
- Target Recruit Count
- 43
- Registration Number
- NCT04176718
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 84
- Registration Number
- NCT04096066
- Locations
- 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹AO di Padova, Padova, Italy
🇮🇹AO Bianchi Melacrino Morelli, Reggio Calabria, Italy
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT04065789
- Locations
- 🇮🇱
Hematology Department Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Kaplan Medical center, Reẖovot, Israel
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 424
- Registration Number
- NCT03989414
- Locations
- 🇺🇸
Local Institution - 110, Winston-Salem, North Carolina, United States
🇨🇿Local Institution - 802, Brno, Czechia
🇨🇿Local Institution - 801, Ostrava-Poruba, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.